Hit multiple targets for maximum benefit in HER2-positive breast cancer, studies suggest
Tuesday, March 8, 2011 - 10:06
in Health & Medicine
Combining targeted therapies might be required for maximum anti-tumor activity when treating HER2-positive breast cancers, according to two new studies by Vanderbilt-Ingram Cancer Center (VICC) investigators.